This content is machine translated BRAFV600 stage IV melanoma Targeted therapy: “real world” data on encorafenib plus binimetinib The BERING-Melanoma multicenter study is monitoring the use of encorafenib with binimetinib in the first- and second-line setting* in patients with advanced BRAFV600-mutated malignant melanoma in everyday care in Germany, Austria,…
